Effects of losartan in women with hypertension and left ventricular hypertrophy: Results from the Losartan Intervention For Endpoint reduction in hypertension study

Hypertension

Volumn 51, Issue 4 PART 2 SUPPL., 2008, Pages 1103-1108

  Os, Ingrid ^a,b   Franco, Veronica ^c   Kjeldsen, Sverre E ^a,e   Manhem, Karin ^f   Devereux, Richard B ^g   Gerdts, Eva ^h,i   Hille, Darcy A ^j   Lyle, Paulette A ^j   Okin, Peter M ^g   Dahlöf, Björn ^f   Oparil, Suzanne ^d  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Gender; Hypertension; Left ventricular hypertrophy; Outcomes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANGINA PECTORIS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEX DISTRIBUTION; STROKE;

EID: 40849116546     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.105296     Document Type: Article

References (26)

1. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA, AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372.
2. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results of the Third National Health and Nutrition Examination Survey. Hypertension. 1995;25:305-313.
3. Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, Wong N, Francis J, Grimm R, Kotchen T, Langer R, Lasser N. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension. 2000;36:780-789.
4. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005;294:466-472.
5. Westheim A, Klemetsrud T, Tretli S, Stokke HP, Olsen H. Blood pressure levels in treated hypertensive patients in general practice in Norway. Blood Press. 2001;10:37-42.
6. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The LIFE Study Group. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10:705-713.
7. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm L, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
8. Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B. Blood pressure reduction and antihypertensive medication use in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin. 2007;23:259-270.
9. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlöf B. Losartan Intervention for Endpoint reduction in hypertension Study Investigators. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention For Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108:684-690.
10. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events: the LIFE study. JAMA. 2004;292:2343-2349.
11. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B. Gender differences in regression of electrocardiographic left ventricular hypertrophy in response to antihypertensive therapy: a LIFE study. J Am Coll Cardiol. 2003;41:230A (abstract).
12. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA. 2006;296:1242-1248.
13. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieslinski A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Storset O. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens. 2006;24:2163-2168.
14. Mann J, Julius S. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press. 1998;7:176-183.
15. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-2051.
16. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald G, Marley JE, Morgan TO, West MJ. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New Eng J Med. 2003;348:583-592.
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
18. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-886.
19. Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Papademetriou V, Skoog I, Zanchetti A. The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press. 2005;14:31-37.
20. Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlof B. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin. A Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;46:770-775.
21. Kristianson K, Fyhrquist F, Devereux RB, Kjeldsen SE, Lindholm LH, Lyle PA, Nieminen MS, Snapinn SM. An analysis of cholesterol control and statin use in the Losartan Intervention For Endpoint reduction in hypertension study. Clin Ther. 2003;25:1186-1199.
22. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson P. Treatment of Mild Hypertension Study: final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713-724.
23. August P, Oparil S. Hypertension in women. In: Oparil S, Weber M, eds. Hypertension. Philadelphia, PA: WB Saunders; 1999:Chapter 63.
24. Os I, Oparil S, Gerdts E, Hoieggen A. Essential hypertension in women. Blood Press. 2004;13:272-278.
25. Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, Hawkins CM, Langford HG. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med. 1991;114:613-620.
26. Grimm RH Jr, Grandis GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, Yunis C, Svendsen K, Liebson PR, Elmer PJ. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29:8-14.